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Conclusions: Symptomatic vein graft stenosis is associated with the
presence of distal vein graft lesions, alternative conduit grafts, and larger
decreases in the ankle-brachial index (ABI). Graft patency after graft revision
is not affected by whether the vein graft stenosis was or was not associated
with symptoms.
Summary: Stenosis of lower extremity vein grafts is often asymptom-
atic. This study was undertaken to characterize symptomatic vs asymptom-
atic vein grafts and to determine if the presence of symptoms influenced
subsequent patency of vein grafts after revision. This was a retrospective
analysis of a prospectively maintained database from a combined University
and Department of Veterans Affairs Vascular Surgical Service. There were
219 lower extremity vein graft revisions performed in 161 patients between
January 1995 and January 2007. Patients with vein graft stenoses were
considered symptomatic if they had recurrence of the symptoms that had
prompted the original placement of the vein graft. Both univariate and
multivariate analysis were used to develop amodel of independent predictors
of symptomatic recurrence. Patency rates for symptomatic and asymptom-
atic stenotic vein grafts were compared after revision.
There were 125 asymptomatic and 94 symptomatic vein graft lesions
revised. Lesions associated with symptoms had a significantly greater drop in
ABI than asymptomatic lesions (0.21  0.03 vs 0.18  0.02, P  .003).
Vein graft stenoses that were located in the distal graft or in the outflow
artery were also more likely to be associated with symptom recurrence (P 
.048). By multivariate analysis, a decrease in ABI (odds ratio, 6.803; 95%
confidence interval [CI], 1.418-32.258; P .02) and use of alternative vein
conduits (odds ratio. 2.633; 95% CI, 1.243-5.578; P  .01) were indepen-
dent predictors of symptomatic vein graft stenosis. There were also strong
trends towards symptomatic recurrence being associated with other systemic
manifestations of atherosclerosis such as cerebrovascular disease or coronary
artery disease (P  .06). Patients with diabetes or renal failure and current
smokers were not more likely to present with recurrent symptoms. Symp-
tomatic stenoses were more frequent in revisions performed between 1 and
2 years postoperatively (56%) than in the first year after the operation (37%,
P .003). Assisted primary patency rates of grafts revised with symptomatic
vs asymptomatic stenoses were not different (82% symptomatic and 88%
asymptomatic at 5 years; P  .30).
Comment:The article defines, for the first time, factors associated with
symptomatic vein graft stenoses. Unfortunately, although stenoses revised in
alternative conduit grafts and stenoses revised 1 year after graft implanta-
tion are more frequently associated with symptoms, a significant number of
patients in those groups also have asymptomatic graft stenosis of sufficient
severity that the graft requires revision. At this time, a life-long policy of
periodic surveillance of lower extremity vein grafts with duplex scanning still
seems prudent.
Shifting paradigms in the treatment of lower extremity vascular dis-
ease: A report of 1000 percutaneous interventions
DeRubertis BG, Faries PL, McKinsey JF, et al. Ann Surg 2007;246:415-
424.
Conclusion: The first-line therapy for patients with chronic lower
extremity ischemia should be a percutaneous intervention.
Summary: The authors report retrospective analysis of 1000 percuta-
neous infrainguinal interventions. Claudication was the indication for inter-
vention in 46.3%, and limb-threatening ischemia was the indication in 52.7%
(rest pain, 27.7%; tissue loss, 72.3%). Patients were treated with a variety of
catheter-based techniques, including angioplasty, angioplasty and stenting,
laser angioplasty, and atherectomy. Femoral, popliteal, and tibial vessels
were treated. Men comprised 57.3% of patients, 58% of patients had diabe-
tes, and chronic renal insufficiency was present in 39%. The 30-day mortality
rate was 0.5%. In patients with claudication, 2-year primary and secondary
patency rates were 62.4% and 79.3%. At 2 years, only 0.5% of claudicant
patients had undergone amputations. In patients with limb-threatening
ischemia, rates for 2-year primary patency, secondary patency, and limb
salvage were 37.4%, 55.4%, and 79.3%, respectively. Predictors of recurrent
disease included limb threat as the indication for intervention (P  .0001),
hypercholesterolemia (P  .001), diabetes (P  .003), coronary artery
disease (P  .047), and TransAtlantic Inter-Society Consensus (TASC) D
lesions (P .050). Of the patients with recurrent disease, 60.3% underwent
a successful percutaneous reintervention, 7.5% required no further interven-
tion, 11.7% underwent bypass, and 20.5% had amputation.
478Comment: This is a retrospective analysis of a large number of patients
treated for evolving indications with continually changing technology. The
results are not surprising, and the predictors of failure not unexpected.
Unfortunately, this lesion-based analysis is out dated. The authors also did
not tell us about those who were medically managed, those treated with
open operations, the nature of the wounds in the patients with critical limb
ischemia, and who underwent primary amputation. There was no quality of
life evaluation in those treated. Compared with most open series of infrain-
guinal revascularization, a high percentage of the patients had claudication.
Overall, the article tells us what a group of surgeons with seemingly relatively
liberal indications for intervention and favoring catheter-based techniques
did. It also tells us a bit about how the intervention worked out. It doesn’t
really tell patients how it will work out for them, nor does it tell surgeons
what they should do.
Effect of statin withdrawal on frequency of cardiac events after vascular
surgery
Schouten O, Hoeks SE, Welten GM, et al. Am J Cardiol 2007;1000:
316-20.
Conclusion: Statin withdrawal in the perioperative period after vascu-
lar surgery is associated with increase risks of perioperative adverse cardiac
events.
Summary: The incidence of adverse cardiac events increases in patients
with acute coronary syndrome who have withdrawal of their statin medica-
tion (J Cardiothorac Anesthes 2003;17:90-100). There are no intravenous
formulas for statins, thus interruption of statins in the postoperative period
occurs frequently, especially in patients with postoperative ileus. In this
study, the authors studied 298 consecutive patients who underwent major
vascular surgery and who were also taking a statin medication. The goal of
the study was to assess the effect of postoperative cardiac outcome after
perioperative statin withdrawal.
Patients were evaluated with detailed cardiac history and determination
of medication use, including the particular type of statin each patient was
taking. Troponin levels were measured on postoperative days 1, 3, and 7,
and 30. Troponin levels were also obtained whenever indicated clinically by
electrocardiographic changes. End points of the study were myocardial
infarction, postoperative troponin release, and a combination of cardiovas-
cular death and nonfatal myocardial infarction. Cox proportional hazard
analysis and multivariant analysis were used to assess the influence of statin
type and the effect of discontinuation of statins on occurrence of study end
points.
Perioperative discontinuation of statin medication was associated with
an increased risk of troponin release (hazard ratio [HR], 4.6; 95% confidence
interval [CI], 2.2-9.6). Statin discontinuation was also associated with an
increased risk of the combination of cardiovascular death and myocardial
infarction (HR, 7.5; 95% CI, 2.8-10.1). Fluvastatin, an extended-release
statin, was associated with fewer perioperative events compared with prava-
statin, simvastatin, and atorvastatin.
Comment: Evidence is accumulating that statin withdrawal in the
perioperative period is harmful for vascular surgical patients. Obviously, this
is not due to perioperative changes in lipid levels but likely involves some of
the pleiotropic effects of statins, such as inhibition of inflammation, anti-
thrombotic effects, and modulation of endothelial function. Pleiotropic
effects are present within hours of statin administration. Such effects can be
rapidly lost with acute withdrawal of a statin medication. Whenever possible,
vascular surgical patients should be started on statins preoperatively and
maintained on statins during their perioperative period.
TGF-Beta and CTGF-Mediated Fibroblast Recruitment Influences
Early Outward Vein Graft Remodeling
Jiang Z, Yu P, Tao M, et al. Am J Physiol Heart Circulatory Physiol 2007;
293: H482-H488.
Conclusions: Elevated wall shear stress increases production of tissue
growth factor- (TGF-) and connective tissue growth factor (CTGF) leading
to increased differentiation of fibroblasts to myofibroblasts. Levels of TGF-
and CTGF correlate inversely with outward remodeling of the vein graft wall.
Summary: Placement of a venous conduit into an arterial system leads
to acute alterations in shear stress in the vein graft wall. Shear influences both
the morphology of the graft wall and intramural growth. Increased wall
shear promotes luminal expansion, and elevated circumferential wall stress
leads to wall thickening and stabilization of luminal diameter. Both TGF-
and CTGF regulate adventitial remodeling. The authors postulate increased
